EVGN

Evogene earns an Underweight rating with a composite score of 28.9 and conviction of one out of five. The regulatory pillar leads at 55, supported by Israel’s jurisdiction posture score of 70 and an enforcement subscore of 80. The market pillar contributes 40 despite the absence of an available quote, limiting price-based confirmation from institutional pricing feeds. Editorial contributes 30, reflecting baseline news and brief subscores without recent CIN newsroom coverage. Fundamentals rank last at 2, as contracting revenue, negative margins, cash consumption, and a small market capitalization overwhelm the modest cash-runway subscore. The resulting pillar mix places Evogene firmly in the Underweight band.

Licensed fundamentals data show year-over-year revenue contracting by 86.3%, while gross margin stands at negative 46.8% and operating margin at negative 952.1%. EBITDA is negative $13.334 million, and the cash-burn ratio is approximately 2.15, consistent with the stated stretched financial condition. Market capitalization is approximately $6.2 million, earning no support from the market-cap tier subscore, while the cash-runway component contributes 15. Net income is reported at zero, but that figure does not offset the negative EBITDA, severe operating deficit, or cash consumption. Primary regulatory filings show no reported regulatory events across either the latest 90-day or 180-day periods, no enforcement hits, and no available latest filing date. That cadence produces only a 25 subscore despite stronger jurisdiction and enforcement readings.

The clearest forward catalyst sits within the strongest pillar: regulatory. Evogene’s Israel jurisdiction posture and clean enforcement record provide the only material base for composite improvement, but conversion requires a visible filing cadence and a substantive regulatory event documented through primary regulatory filings. Fresh filings could lift the weakest component inside the regulatory pillar, improve disclosure visibility, and provide a verifiable foundation for subsequent CIN newsroom coverage or renewed institutional pricing support. The single most important signal to watch is the appearance of a current primary regulatory filing that converts regulatory posture into measurable filing cadence.